Novel agent for Alzheimer's treatment using dynamin 1 peptide
Summary
The USPTO has published a new patent application (US20260083826A1) from the Okinawa Institute of Science and Technology School Corporation for a novel agent to treat Alzheimer's disease. The application describes a peptide corresponding to dynamin 1, potentially encapsulated in nanoparticles for improved brain delivery.
What changed
This document is a USPTO patent application publication for a novel agent for treating Alzheimer's disease. The application, filed by the Okinawa Institute of Science and Technology School Corporation, describes a prophylactic and/or therapeutic agent comprising a peptide corresponding to dynamin 1, preferably encapsulated in nanoparticles or linked to a peptide sequence for improved brain delivery. The patent application is identified as US20260083826A1 and was filed on September 13, 2023.
As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signals potential future developments in Alzheimer's treatment and may be of interest to pharmaceutical companies and researchers in the field. Compliance officers in the pharmaceutical sector should monitor patent filings for emerging therapeutic technologies and potential intellectual property considerations.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NEW SYNTHETIC DRUGS FOR TREATING ALZHEIMER'S DISEASE
Application US20260083826A1 Kind: A1 Mar 26, 2026
Assignee
OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION
Inventors
Tetsuya HORI, Tomoyuki TAKAHASHI, Zacharie TAOUFIQ, Kohji TAKEI, Hiroshi YAMADA
Abstract
The present invention aims to provide a novel agent for treating Alzheimer's disease, a method for treating Alzheimer's disease, a method for screening for a candidate substance for a therapeutic drug for Alzheimer's disease, and the like. The present invention is a prophylactic and/or therapeutic agent for Alzheimer's disease comprising a peptide corresponding to dynamin 1. The peptide preferably corresponds to dynamin 1-pleckstrin-homology domain or dynamin 1-proline rich domain. In addition, the peptide is preferably encapsulated in nano-particles or linked to a peptide sequence that improve delivery of the peptide into the brain.
CPC Classifications
A61K 38/46 A61P 25/28 C12Y 306/05005 G01N 33/573 G01N 2333/914 G01N 2500/02
Filing Date
2023-09-13
Application No.
19111601
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.